CLINICAL_TRIALS trial_result · 2022-02-10

Clinical Trial Update: Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease [Phase 1, Phase 2]

A combined Phase 1/2 trial assessing safety and tolerability of WVE-120101 in Huntington's disease was terminated with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Wave Life Sciences Ltd. | Conditions: Huntington's Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-02-10